Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ NSAID final report

Executive Summary

Agency for Healthcare Research & Quality publishes final report on comparative effectiveness of osteoarthritis treatments. Report makes no significant departures from draft, which found that Pfizer's COX-2 inhibitor Celebrex has a safety benefit vs. non-selective NSAIDs (1"The Pink Sheet" Feb. 28, 2006, p. 23)...

You may also be interested in...



Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says

The safety benefit of Pfizer's COX-2 inhibitor Celebrex compared to non-selective nonsteroidal anti-inflammatory drugs is affirmed in a draft report from the Agency for Healthcare Research & Quality on osteoarthritis treatments

Setback For Athenex, Hanmi As CRL Requests New Trial

Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.

Chordia Looks To Forge Own Path In Oncology

Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel